DUGGAN ROBERT W 4
4 · Summit Therapeutics Inc. · Filed May 1, 2025
Insider Transaction Report
Form 4
DUGGAN ROBERT W
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Award
Stock Option (right to buy)
2025-04-29+1,040,000→ 1,040,000 total(indirect: By Spouse)Exercise: $1.06Exp: 2032-06-28→ Common Stock (1,040,000 underlying) - Award
Stock Option (right to buy)
2025-04-29+9,590,558→ 9,590,558 total(indirect: By Spouse)Exercise: $1.68Exp: 2033-10-13→ Common Stock (9,590,558 underlying) - Award
Stock Option (right to buy)
2025-04-29+400,000→ 400,000 total(indirect: By Spouse)Exercise: $1.29Exp: 2032-09-09→ Common Stock (400,000 underlying)
Footnotes (3)
- [F1]Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025.
- [F2]Not applicable.
- [F3]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.